IMFINZI® (DURVALUMAB) REGIMEN DEMONSTRATED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN DISEASE-FREE SURVIVAL FOR HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER IN POTOMAC PHASE III TRIAL

Reuters · 05/09 11:00

Please log in to view news